2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Tuesday, November 15, 2016

11:00AM-12:30PM: Abstract Number: 2984

Novel Anti-Malarial Drug Derivative Inhibited Type I Interferon Production and Autoimmune Inflammation through Inhibition of CGAS-Sting Pathway in Trex1-/- Mouse

Plenary Session III: Discovery 2016

11:00AM-12:30PM: Abstract Number: 2985

Practice-Level Variation in Quality of Care in the Acr’s Rheumatology Informatics System for Effectiveness (RISE) Registry

Plenary Session III: Discovery 2016

11:00AM-12:30PM: Abstract Number: 2986

Trends and Determinants of Osteoporosis Prevention and Management in Patients with Rheumatoid Arthritis Compared to Osteoarthritis

Plenary Session III: Discovery 2016

11:00AM-12:30PM: Abstract Number: 2982

Tumor Necrosis Factor Inhibitors and the Risk of Malignancy in the Treatment of Juvenile Idiopathic Arthritis

Plenary Session III: Discovery 2016

2:30PM-4:00PM: Abstract Number: 2991

A Molecular Signature Based on IFN Gene Signature and Serology Defines Two Populations of Patients with Different Baseline Disease Activity in a Large Multinational Phase 3 SLE Trial Population

2016 Rheumatology Research Foundation Edmond L. Dubois, MD Memorial Lectureship

2:30PM-4:00PM: Abstract Number: 3034

A Selective JAK1 Inhibitor, Filgotinib Suppresses Lymphocytic Infiltration in Salivary Gland of Non Obese Diabetic Mice Via Suppression of BAFF and Chemokine Production of Salivary Gland Epithelial Cells

Sjögren's Syndrome I: Clinical Insights

2:30PM-4:00PM: Abstract Number: 3028

A Single Infusion of Rituximab Delays the Onset of Arthritis in Subjects at High Risk of Developing RA

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy III: Small Molecules and Early Intervention

2:30PM-4:00PM: Abstract Number: 3032

Abnormalities in the Biological or Haematological Domain of the Essdai Predict an Increase in Systemic Disease Activity the Year after: 5-Year Data from the Prospective Multicenter Assess Cohort

Sjögren's Syndrome I: Clinical Insights

2:30PM-4:00PM: Abstract Number: 3041

Age-Related Defects in the Immune System of Patients with GCA

Vasculitis III: Pathogenic Mechanisms

2:30PM-4:00PM: Abstract Number: 3039

Anti-IL-17A, but Not Anti-TNF, Can Halt Pathological New Bone Formation in Experimental Spondyloarthritis

Spondylarthropathies Psoriatic Arthritis – Pathogenesis, Etiology I

2:30PM-4:00PM: Abstract Number: 3022

Autoantibodies to Peptidylarginine Deiminase 2 Protect Against Radiographic Progression in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Human Etiology and Pathogenesis I

2:30PM-4:00PM: Abstract Number: 2999

Autologous Osteoblastic Cells Versus Concentrated Bone Marrow Implantation in Osteonecrosis of the Femoral Head: A Randomized Controlled Single Blind Study

Orthopedics, Low Back Pain and Rehabilitation

2:30PM-4:00PM: Abstract Number: 2994

Binding of Periostin to Discoidin Domain Receptor-1 (DDR1) Promotes Cartilage Degeneration By Inducing MMP-13 Expression

Biology and Pathology of Bone and Joint

2:30PM-4:00PM: Abstract Number: 3037

Calprotectin Is Highly Upregulated in Inflamed Axial Entheses in SKG Mice

Spondylarthropathies Psoriatic Arthritis – Pathogenesis, Etiology I

2:30PM-4:00PM: Abstract Number: 2990

Cancer in Systemic Lupus Erythematosus: Results from the Systemic Lupus International Collaborating Clinics Inception Cohort

2016 Rheumatology Research Foundation Edmond L. Dubois, MD Memorial Lectureship

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].